MediciNova Ebitda from 2010 to 2024

MNOV Stock  USD 2.17  0.01  0.46%   
MediciNova EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -10.4 M in 2024. During the period from 2010 to 2024, MediciNova EBITDA regression line of quarterly data had r-squared of  0.14 and coefficient of variation of (36.40). View All Fundamentals
 
EBITDA  
First Reported
2004-03-31
Previous Quarter
-3 M
Current Value
-3.3 M
Quarterly Volatility
4.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MediciNova financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MediciNova's main balance sheet or income statement drivers, such as Interest Expense of 679.1 K, Other Operating Expenses of 14.5 M or Research Development of 7.9 M, as well as many indicators such as Price To Sales Ratio of 107, Dividend Yield of 0.0 or PTB Ratio of 1.63. MediciNova financial statements analysis is a perfect complement when working with MediciNova Valuation or Volatility modules.
  
Check out the analysis of MediciNova Correlation against competitors.
For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.

Latest MediciNova's Ebitda Growth Pattern

Below is the plot of the Ebitda of MediciNova over the last few years. It is MediciNova's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MediciNova's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

MediciNova Ebitda Regression Statistics

Arithmetic Mean(10,844,644)
Coefficient Of Variation(36.40)
Mean Deviation2,875,321
Median(10,847,644)
Standard Deviation3,947,546
Sample Variance15.6T
Range14.1M
R-Value(0.37)
Mean Square Error14.5T
R-Squared0.14
Significance0.18
Slope(325,329)
Total Sum of Squares218.2T

MediciNova Ebitda History

2024-10.4 M
2023-9.9 M
2022-13.9 M
2021-10.2 M
2020-14.2 M
2019-14 M
2018-15.6 M

About MediciNova Financial Statements

MediciNova investors use historical fundamental indicators, such as MediciNova's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MediciNova. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-9.9 M-10.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MediciNova Stock Analysis

When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.